<SEC-DOCUMENT>0001213900-26-070398.txt : 20260622
<SEC-HEADER>0001213900-26-070398.hdr.sgml : 20260622
<ACCEPTANCE-DATETIME>20260622085017
ACCESSION NUMBER:		0001213900-26-070398
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260622
FILED AS OF DATE:		20260622
DATE AS OF CHANGE:		20260622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		261105084

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Enlivex Therapeutics Ltd.
		DATE OF NAME CHANGE:	20190326

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0295405-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: June 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ENLIVEX LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On June
22, 2026, Enlivex Ltd.,</FONT> a company organized under the laws of the State of Israel, <FONT STYLE="background-color: white">issued
a press release providing an update on its RAIN token holdings. A copy of the press release is furnished herewith as Exhibit 99.1 and
is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea029540501ex99-1.htm">Press Release</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">Enlivex Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%"><FONT STYLE="font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Name:&nbsp; </TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD STYLE="vertical-align: top">Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 22, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#8239;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea029540501ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%"><IMG SRC="ea029540501_ex99-1img1.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: top; text-align: right; width: 50%">June 22, 2026</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately
$1.14 Billion</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion</FONT><SUP>1</SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:
ENLV, &ldquo;Enlivex&rdquo; or the &ldquo;Company&rdquo;), a quality longevity company powered by a prediction markets treasury, today provided
an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately
$1.14 billion<SUP>1</SUP>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s treasury metrics, as reflected on its public market data
dashboard, indicate a Treasury NAV per Share of $4.67<SUP>1</SUP> as of June 20, 2026, based on current RAIN token holdings relative to
total number of the Company&rsquo;s ordinary shares outstanding. The updated unaudited mark-to-market treasury metrics are publicly available
on the Company&rsquo;s website at https://enlivex.com/dashboard/. Detailed information about the token&rsquo;s listing on various exchanges,
daily trading volume and other parameters can be found on https://coinmarketcap.com/currencies/rain/.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enlivex</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra&trade;,
an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related
osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol,
the leading decentralized prediction markets infrastructure on Arbitrum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This dual strategy combines the development of quality longevity therapeutics
with exposure to the emerging prediction markets ecosystem.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Forward-looking
statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 12pt"><B></B></FONT>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified
by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo;
&ldquo;suggests,&rdquo; &ldquo;target,&rdquo; &ldquo;has the potential to,&rdquo; &ldquo;goal,&rdquo; and other words of similar meaning,
including statements relating to the anticipated benefits of the Company&rsquo;s digital asset treasury strategy; the assets to be held
by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange
listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on
the liquidity of the Company&rsquo;s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets;
the Company&rsquo;s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions;
competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market
opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities
for, ALLOCETRA&trade; programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">Valuation calculated using the closing price of the token as
quoted on https://coinmarketcap.com/currencies/rain/</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.enlivex.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: left; width: 50%"><IMG SRC="ea029540501_ex99-1img1.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: top; text-align: right; width: 50%">June 22, 2026</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each forward-looking statement contained in this press release is subject
to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable
risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company&rsquo;s digital asset
treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company&rsquo;s operations
and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks
associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the
Company&rsquo;s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition
in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty
regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks
and uncertainties identified in the Company&rsquo;s filings with the Securities and Exchange Commission. The forward-looking statements in this
press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements,
except as required by applicable law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Enlivex contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B></B></FONT>Shachar
Shlosberger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Enlivex Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">shachar@enlivex.com</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.enlivex.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea029540501_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029540501_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X )<# 2(  A$! Q$!_\0
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MGAJSTC0W^B_V;_A_\=/^#>G_ (+??LN?L">"/VA_B)\:_P#@GQ^WO8K9>$/
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MRVTK3X)X[2'_ #+?AU_R@M_X. /^T@'[-/\ ZOS3*_0+]H2SN/\ @G5\3/\
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MY=6^(OC01%-1^(OQ,U>.*?Q;XPU&1T20I>7P^QZ/:&.&/3="L]-L(X(S#(7
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MI+B>!M161?U'_P"#C[]B#PK\(?VW?V+?^"H_CS]ET_M2_L/_  ^\&:%^SO\
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M_P#A#OB#K.@7OBWPQ]DN;BXN+;^Q-7L?(GGFEBV22NS '\ OQ%_X(Y?M:?\
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>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
